688091.SH
上海谊众
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 36.96
−7.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 324.2M | 316.1M | 173.5M | 360.3M | 236.0M |
| Cost of Revenue | 51.8M | 53.4M | 13.3M | 23.6M | 17.0M |
| Gross Profit | 272.4M | 262.7M | 160.2M | 336.7M | 219.0M |
| Operating Expenses | |||||
| R&D Expense | 104.5M | 86.4M | 37.2M | 22.5M | 7.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 14.1M | 15.8M | 27.6M | 40.9M | 9.6M |
| Selling & Marketing Expense | 104.9M | 110.0M | 115.5M | 106.6M | 89.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 211.5M | 199.9M | 163.9M | 144.7M | 89.2M |
| Cost and Expenses | 263.3M | 253.2M | 177.3M | 168.3M | 106.1M |
| Operating Income (EBIT) | 62.7M | 62.3M | 9.5M | 195.5M | 151.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 62.6M | 61.1M | 4.8M | 186.9M | 149.6M |
| Income Tax Expense | (5.9M) | (3.4M) | (2.2M) | 25.3M | 6.7M |
| Bottom Line | |||||
| Net Income | 68.5M | 64.6M | 7.0M | 161.6M | 142.9M |
| Earnings from Cont. Ops | 68.5M | 64.6M | 7.0M | 161.6M | 142.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 68.5M | 64.6M | 7.0M | 161.6M | 142.9M |
| Per Share | |||||
| Basic EPS | CN¥0.33 | CN¥0.32 | CN¥0.03 | CN¥1.02 | CN¥0.99 |
| Diluted EPS | CN¥0.33 | CN¥0.32 | CN¥0.03 | CN¥1.02 | CN¥0.99 |
| Revenue Per Share | CN¥1.61 | CN¥1.57 | CN¥0.75 | CN¥2.27 | CN¥1.64 |
| Shares | |||||
| Basic Shares Outstanding | 201.9M | 201.7M | 232.5M | 158.4M | 144.3M |
| Diluted Shares Outstanding | 201.9M | 201.7M | 232.5M | 158.4M | 144.3M |
| Profitability Metrics | |||||
| EBITDA | — | 76.3M | 21.4M | 203.6M | 158.0M |
| D&A | — | 14.1M | 11.9M | 8.2M | 6.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026